Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
An Open-Label, Extension Study of the Effects of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  12/31/1969
University of Virginia
mi
from
Charlottesville, VA
Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
An Open-Label, Extension Study of the Effects of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 12/31/1969
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
An Open-Label, Extension Study of the Effects of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  12/31/1969
Independent Psychiatric Consultants
mi
from
Waukesha, WI
Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
An Open-Label, Extension Study of the Effects of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 12/31/1969
Independent Psychiatric Consultants
mi
from
Waukesha, WI
Click here to add this to my saved trials
Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
An Open-Label, Extension Study of the Effects of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  12/31/1969
Division of Rehabilitation and Aged Care
mi
from
Hornsby,
Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
An Open-Label, Extension Study of the Effects of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 12/31/1969
Division of Rehabilitation and Aged Care
mi
from
Hornsby,
Click here to add this to my saved trials
The Effect of Horizant (Gabapentin Enacarbil) on Augmentation
To Examine the Effect of Horizant (Gabapentin Enacarbil) in Primary Restless Legs Syndrome (RLS) Patients Who Are on Dopaminergic Agents and Exhibiting Augmentation
Status: Enrolling
Updated:  12/31/1969
University of Missouri Health Care
mi
from
Columbia, MO
The Effect of Horizant (Gabapentin Enacarbil) on Augmentation
To Examine the Effect of Horizant (Gabapentin Enacarbil) in Primary Restless Legs Syndrome (RLS) Patients Who Are on Dopaminergic Agents and Exhibiting Augmentation
Status: Enrolling
Updated: 12/31/1969
University of Missouri Health Care
mi
from
Columbia, MO
Click here to add this to my saved trials
Early Independent Adaptive Arm and Hand Rehab
Early Independent Adaptive Arm and Hand Rehabilitation Post Stroke
Status: Enrolling
Updated:  12/31/1969
New York University Langone Medical Center
mi
from
New York, NY
Early Independent Adaptive Arm and Hand Rehab
Early Independent Adaptive Arm and Hand Rehabilitation Post Stroke
Status: Enrolling
Updated: 12/31/1969
New York University Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
MIND Diet Intervention and Cognitive Decline
MIND Diet Intervention to Prevent Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Rush University
mi
from
Chicago, IL
MIND Diet Intervention and Cognitive Decline
MIND Diet Intervention to Prevent Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Rush University
mi
from
Chicago, IL
Click here to add this to my saved trials
MIND Diet Intervention and Cognitive Decline
MIND Diet Intervention to Prevent Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Harvard School of Public Health
mi
from
Boston, MA
MIND Diet Intervention and Cognitive Decline
MIND Diet Intervention to Prevent Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Harvard School of Public Health
mi
from
Boston, MA
Click here to add this to my saved trials
Contralaterally Controlled FES for Hand Opening in Hemiplegic Cerebral Palsy
Contralaterally Controlled Functional Electrical Stimulation for Hand Opening in Hemiplegic Cerebral Palsy: Pilot Randomized Controlled Trial
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Contralaterally Controlled FES for Hand Opening in Hemiplegic Cerebral Palsy
Contralaterally Controlled Functional Electrical Stimulation for Hand Opening in Hemiplegic Cerebral Palsy: Pilot Randomized Controlled Trial
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Contralaterally Controlled FES for Hand Opening in Hemiplegic Cerebral Palsy
Contralaterally Controlled Functional Electrical Stimulation for Hand Opening in Hemiplegic Cerebral Palsy: Pilot Randomized Controlled Trial
Status: Enrolling
Updated:  12/31/1969
MetroHealth Med Ctr
mi
from
Cleveland, OH
Contralaterally Controlled FES for Hand Opening in Hemiplegic Cerebral Palsy
Contralaterally Controlled Functional Electrical Stimulation for Hand Opening in Hemiplegic Cerebral Palsy: Pilot Randomized Controlled Trial
Status: Enrolling
Updated: 12/31/1969
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Effects of Early Vestibular Rehabilitation in Patients With Dizziness and Balance Disorders After Sport Concussion
Effects of Early Vestibular Rehabilitation Compared to Standard Care in Patients With Dizziness and Balance Disorders After Sport and Recreation Concussion
Status: Enrolling
Updated:  12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Effects of Early Vestibular Rehabilitation in Patients With Dizziness and Balance Disorders After Sport Concussion
Effects of Early Vestibular Rehabilitation Compared to Standard Care in Patients With Dizziness and Balance Disorders After Sport and Recreation Concussion
Status: Enrolling
Updated: 12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Ideal Sedation for Stroke Thrombectomy
Ideal Sedation for Stroke Thrombectomy
Status: Enrolling
Updated:  12/31/1969
Los Robles Hospital and Medical Center
mi
from
Thousand Oaks, CA
Ideal Sedation for Stroke Thrombectomy
Ideal Sedation for Stroke Thrombectomy
Status: Enrolling
Updated: 12/31/1969
Los Robles Hospital and Medical Center
mi
from
Thousand Oaks, CA
Click here to add this to my saved trials
Functional Viability Duck Duck Punch
Establishing the Functional Viability and Dose-response of Duck, Duck Punch: A Stroke Rehabilitation Computer Game
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Functional Viability Duck Duck Punch
Establishing the Functional Viability and Dose-response of Duck, Duck Punch: A Stroke Rehabilitation Computer Game
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Probable Alzheimer's Disease or Progressive Supranuclear Palsy Compared With Healthy Volunteers
Status: Enrolling
Updated:  12/31/1969
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Probable Alzheimer's Disease or Progressive Supranuclear Palsy Compared With Healthy Volunteers
Status: Enrolling
Updated: 12/31/1969
Molecular Neuroimaging, LLC
mi
from
New Haven, CT
Click here to add this to my saved trials
Stroke COunseling for Risk REduction
Stroke Counseling for Risk Reduction in Young Adult African Americans
Status: Enrolling
Updated:  12/31/1969
Georgia State University
mi
from
Atlanta, GA
Stroke COunseling for Risk REduction
Stroke Counseling for Risk Reduction in Young Adult African Americans
Status: Enrolling
Updated: 12/31/1969
Georgia State University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Proprioception and Meditation
The Effects of Yoga Based Meditation on Proprioception in Individuals With Parkinson's Disease
Status: Enrolling
Updated:  12/31/1969
Laboratory of Neruomuscular Research and Active Aging
mi
from
Coral Gables, FL
Proprioception and Meditation
The Effects of Yoga Based Meditation on Proprioception in Individuals With Parkinson's Disease
Status: Enrolling
Updated: 12/31/1969
Laboratory of Neruomuscular Research and Active Aging
mi
from
Coral Gables, FL
Click here to add this to my saved trials
The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke
The Effect of Treatment With the PathMaker Myoregulator Neuromodulation System Incorporating Trans-spinal Direct Current Stimulation (tsDCS) in Patients With Severe Hand Spasticity After Stroke
Status: Enrolling
Updated:  12/31/1969
The Feinstein Institute for Medical Research
mi
from
Manhasset, NY
The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke
The Effect of Treatment With the PathMaker Myoregulator Neuromodulation System Incorporating Trans-spinal Direct Current Stimulation (tsDCS) in Patients With Severe Hand Spasticity After Stroke
Status: Enrolling
Updated: 12/31/1969
The Feinstein Institute for Medical Research
mi
from
Manhasset, NY
Click here to add this to my saved trials
Constraint-induced Movement Therapy to Improve Gait and Mobility of People With Chronic Stroke
Constraint-induced Movement Therapy to Improve Gait and Mobility of People With Chronic Stroke
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Constraint-induced Movement Therapy to Improve Gait and Mobility of People With Chronic Stroke
Constraint-induced Movement Therapy to Improve Gait and Mobility of People With Chronic Stroke
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
COmparisoN of High-sensitivity Cardiac TRoponin I and T ASsays Trial
COmparisoN of High-sensitivity Cardiac TRoponin I and T ASsays Trial
Status: Enrolling
Updated:  12/31/1969
Hennepin County Medical Center
mi
from
Minneapolis, MN
COmparisoN of High-sensitivity Cardiac TRoponin I and T ASsays Trial
COmparisoN of High-sensitivity Cardiac TRoponin I and T ASsays Trial
Status: Enrolling
Updated: 12/31/1969
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial site
mi
from
Phoenix, AZ
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Aurora, CO
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Aurora, CO
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Tampa, FL
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Lexington, KY
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Lexington, KY
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Chesterfield, MO
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Chesterfield, MO
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Las Vegas, NV
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Teaneck, NJ
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Teaneck, NJ
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Albuquerque, NM
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Patchogue, NY
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Patchogue, NY
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial site
mi
from
Columbus, OH
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial site
mi
from
Columbus, OH
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Pittsburgh, PA
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial site
mi
from
San Antonio, TX
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial site
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial site
mi
from
Seattle, WA
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)
ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial site
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Carlsbad, CA
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Carlsbad, CA
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Long Beach, CA
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Pasadena, CA
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Pasadena, CA
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Stanford, CA
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Stanford, CA
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Miami, FL
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Miami, FL
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Northbrook, IL
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Northbrook, IL
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Kansas City, KA
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Detroit, MI
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Amherst, NY
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Amherst, NY
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Westerville, OH
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Westerville, OH
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Franklin, TN
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Franklin, TN
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Knoxville, TN
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Dallas, TX
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Trial Site
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated:  12/31/1969
TG Therapeutics RMS Investigational Site
mi
from
Round Rock, TX
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)
Status: Enrolling
Updated: 12/31/1969
TG Therapeutics RMS Investigational Site
mi
from
Round Rock, TX
Click here to add this to my saved trials
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Xenoscience Inc.
mi
from
Phoenix, AZ
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Xenoscience Inc.
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Neuro-Pain Medical Center
mi
from
Fresno, CA
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Neuro-Pain Medical Center
mi
from
Fresno, CA
Click here to add this to my saved trials
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Meridien Research
mi
from
Tampa, FL
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Meridien Research
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 1 Open-label Study of the Safety, Tolerability, and Pharmacokinetics of d- and l-Amphetamine After Multiple Daily Doses of SHP465 6.25 mg Administered in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder
Status: Enrolling
Updated:  12/31/1969
Preferred Research Partners, Inc.
mi
from
Little Rock, AR
Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 1 Open-label Study of the Safety, Tolerability, and Pharmacokinetics of d- and l-Amphetamine After Multiple Daily Doses of SHP465 6.25 mg Administered in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder
Status: Enrolling
Updated: 12/31/1969
Preferred Research Partners, Inc.
mi
from
Little Rock, AR
Click here to add this to my saved trials
Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 1 Open-label Study of the Safety, Tolerability, and Pharmacokinetics of d- and l-Amphetamine After Multiple Daily Doses of SHP465 6.25 mg Administered in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder
Status: Enrolling
Updated:  12/31/1969
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 1 Open-label Study of the Safety, Tolerability, and Pharmacokinetics of d- and l-Amphetamine After Multiple Daily Doses of SHP465 6.25 mg Administered in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder
Status: Enrolling
Updated: 12/31/1969
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Click here to add this to my saved trials